Related Experiment Videos
Beta(2)-microglobulin amyloidosis: effects of ultrapure dialysate and type of dialyzer membrane
Gerhard Lonnemann1, Karl M Koch
1Department of Nephrology, Medizinische Hochschule Hannover, Hannover, Germany. GLonnemann@t-online.de
Abstract:
The available data on the pathophysiology of beta(2)-microglobulin amyloidosis (beta(2)mA) suggest that this progressive disease associated with end-stage renal failure develops in several consecutive phases. First, declining kidney function leads to retention of beta(2) microglobulin (beta(2)m) and its deposition preferentially in the synovial tissue of bigger joints such as wrists, shoulders, and hips. Second, at the site of deposition, formation of unique amyloid fibrils, whose major component is beta(2)m, takes place. Deposition and fibril formation occur in the absence of modification of beta(2)mA by advanced glycoxidation end products and also in the absence of a local inflammatory response. It is later, in the third phase, that advanced glycoxidation end product modification of beta(2)m induces a local inflammatory response by attracting macrophages chemotactically and by stimulating these cells to produce and release proinflammatory cytokines. In addition, unmodified beta(2)m itself induces inflammatory activities such as upregulation of cyclooxygenase-2 and metalloproteinase-1. The severity of the local inflammation seems to determine the degree of the destructive processes in tissue and bone accompanying beta(2)mA.
Insights
Beta(2)-microglobulin amyloidosis (beta(2)mA) progresses through phases, starting with beta(2)m deposition in joints. Inflammation, driven by modified beta(2)m, causes tissue and bone destruction in advanced renal failure.
Area of Science:
- Nephrology
- Rheumatology
- Pathophysiology
Background:
- Beta(2)-microglobulin amyloidosis (beta(2)mA) is a progressive condition linked to end-stage renal failure.
- Pathophysiology involves beta(2)m retention and deposition in joints.
Purpose of the Study:
- To elucidate the phased pathophysiology of beta(2)mA.
- To understand the role of beta(2)m modification and inflammation in disease progression.
Main Methods:
- Review of available data on beta(2)mA pathophysiology.
- Analysis of beta(2)m deposition, fibril formation, and inflammatory responses.
Main Results:
- Beta(2)mA develops in distinct phases: beta(2)m retention and deposition, amyloid fibril formation, and inflammatory response.
- Inflammation is triggered by advanced glycoxidation end product modification of beta(2)m, attracting macrophages and inducing cytokine release.
- Unmodified beta(2)m also contributes to inflammation by upregulating COX-2 and MMP-1.
- Inflammation severity correlates with tissue and bone destruction.
Conclusions:
- Beta(2)mA progression is a multi-phase process involving beta(2)m deposition and subsequent inflammation.
- Inflammatory mediators play a crucial role in the destructive nature of beta(2)mA.
- Understanding these phases is key to managing beta(2)mA in patients with renal failure.